Compare ACT & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACT | CRSP |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.9B |
| IPO Year | 2021 | 2016 |
| Metric | ACT | CRSP |
|---|---|---|
| Price | $42.73 | $51.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $44.25 | ★ $70.29 |
| AVG Volume (30 Days) | 226.2K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 4.52 | N/A |
| Revenue | ★ $1,235,827,000.00 | $289,590,000.00 |
| Revenue This Year | $4.06 | $807.72 |
| Revenue Next Year | $2.33 | $172.52 |
| P/E Ratio | $9.47 | ★ N/A |
| Revenue Growth | 2.83 | ★ 9169.85 |
| 52 Week Low | $33.94 | $33.03 |
| 52 Week High | $44.80 | $78.48 |
| Indicator | ACT | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 47.95 |
| Support Level | $39.43 | $50.91 |
| Resistance Level | $42.80 | $60.45 |
| Average True Range (ATR) | 0.91 | 2.70 |
| MACD | -0.03 | -0.45 |
| Stochastic Oscillator | 38.34 | 23.22 |
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.